王曉蓉　應(yīng)翔

[關(guān)鍵詞] 青少年;抽動(dòng)障礙;硫必利;氟哌啶醇;神經(jīng)遞質(zhì)

[中圖分類(lèi)號(hào)] R749.94? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] B? ? ? ? ? [文章編號(hào)] 1673-9701（2021）22-0028-04

Comparison clinical efficacy of tiapride and haloperidol in the treatment of tic disorder in adolescents

WANG Xiaorong? ?YING Xiang

Department of Psychiatry， the Second Hospital of Jinhua in Zhejiang Province， Jinhua? ?321016， China

[Abstract] Objective To compare the clinical efficacy of tiapride and haloperidol in the treatment of tic disorder in adolescents. Methods A total of 92 patients with tic disorder admitted to and treated in our hospital from October 2018 to November 2019 were randomly selected as the research objects. They were divided into the control group （n=46） and the observation group （n=46）. Patients in the control group were treated with haloperidol， and those in the observation group were treated with tiapride. The clinical efficacy， tic severity score， neurotransmitter indices [including noradrenaline （NE）， dopamine （DA）， 5-hydroxytryptamine （5-HT）] and adverse reactions （ARs） were compared between the two groups. Results The total effective rate of the observation group was 97.82%， which was significantly higher than 86.96% of the control group， with statistically significant difference （P<0.05）. Before treatment， there was no significant difference in the scores of Yale global tic severity scale （YGTSS） between the two groups （P>0.05）. After treatment， the YGTSS score of the observation group was （24.89±3.42）， which was lower than （26.71±3.56） in the control group， with statistically significant difference （P<0.05）. Before and after treatment， there was statistically significant difference in YGTSS scores in the observation group and the control group （P<0.05）. After treatment， the NE level in the observation group was （36.54±10.03） ng/mL， which was significantly higher than （32.22±9.01） ng/mL in the control group. The levels of DA and 5-HT were （13.11±3.81） ng/mL and （56.71±11.58） ng/mL， respectively， which were significantly lower than （15.17±4.35） ng/mL and （63.51±12.55） ng/mL in the control group， with statistically significant differences （P<0.05）. Before and after treatment， the levels of NE， DA and 5-HT in the observation group and the control group were significantly different （P<0.05）. The incidence of ARs in the observation group was 6.52%， which was significantly lower than 19.57% in the control group， with statistically significant difference （P<0.05）. Conclusion In the treatment of tic disorder， tiapride can improve the clinical efficacy of patients， reduce the degree of damage， regulate pituitary hormone secretion， regulate autonomic neurological function， improve the clinical therapy effects of patients and reduce ARs. Therefore， it is worthy of promotion.